Latest news with #Sayour
Sky News AU
5 days ago
- Sky News AU
Sydney influencer Hasan Sayour identified as dog breeder involved in alleged assault at dog show he was banned from
A dog breeder arrested for allegedly trying to force his way into a dog show and getting into a fight with a female staff member has been identified as a Sydney man with a significant social media following. NSW Police announced on Friday that Raptor Squad officers had charged a member of a 'notorious dog breeding group" in relation to an incident in Sydney's Castle Hill in May. Police were told a dog breeder and his associates were attempting to enter an American Bull Terrier dog show in Castle Hill they had been banned from, a police statement said. The man allegedly pushed a staff member to access the show ring, before displaying a dog breeding banner on the floor. He then allegedly got into a physical altercation with a female staff member after the employee tried to remove the banner. Police say the breeder and his associates left the dog show a short time later. A 33-year-old man was arrested by Raptor Squad officers about midday on Thursday in the suburb of Greenfield Park. The man was taken Fairfield Police Station and charged with common assault and enter enclosed land not prescribed premises without lawful excuse. He was granted strict bail conditions to appear in Fairfield Local Court on August 20, police have said. The Daily Telegraph have reported the man arrested is Hasan Sayour, who is behind dog breeding business 'Federal Bullies' which boasts 286,000 Instagram followers. The social media page regularly posts pictures of Mr Sayour sporting the Federal Bullies branding alongside dogs and puppies. Images released by NSW Police of their arrest on Thursday appear to show Mr Sayour handcuffed and wearing Federal Bullies apparel as he is led by officers from a residence into an unmarked vehicle. Mr Sayour is the nephew of Kings Cross identity John Ibrahim, according to The Daily Telegraph.
Newsweek
6 days ago
- Health
- Newsweek
Cancer Vaccine Breakthrough: What We Know About 'Exciting' Early Data
Based on facts, either observed and verified firsthand by the reporter, or reported and verified from knowledgeable sources. Researchers at the University of Florida are moving closer to developing what they have described as a "universal" cancer vaccine, according to a study published in Nature Biomedical Engineering on July 18. The vaccine would work by "waking the immune system up against something that looks dangerous, and then that response spills over to recognize and reject the tumor," Dr. Elias Sayour, co-author of the study, director of the Pediatric Cancer Immunotherapy Initiative, and principal investigator at the RNA Engineering Laboratory at the University of Florida, told Newsweek. Sayour said that he believed the vaccine would apply to all types of cancer, because the treatment would result in the immune system being able to "recognize and reject all forms of cancer." "In active cancers, the immune system has been fooled or lies dormant," he said. "This approach can wake it up, restoring it in the fight against cancer." Sayour said that the concept of the treatment is being investigated in ongoing clinical human trials. If all goes well, it "could be a completely new paradigm to treat all cancer patients." Photo-illustration by Newsweek/Getty Most people think of vaccines as being "preventive," and taken to "prevent or lessen the impact of certain infectious diseases," David Braun, a professor of medicine and member of the Center of Molecular and Cellular Oncology at Yale Cancer Center, told Newsweek. While there are some efforts in this field for cancer, the majority of trials investigate "therapeutic" vaccines, which are used to try to treat cancer once it develops, he said. "Most cancer vaccines try to steer the immune system to attack a patient's cancer, which makes it very difficult to create a universal vaccine," Braun, who is not associated with the study, said. Referring to the study, Braun said the research team is proposing "the idea that the vaccination itself, somewhat irrespective of what it is targeting, might stimulate the immune system enough to attack cancer." "It is a very intriguing idea, but would need to be tested very carefully in clinical studies," he added. What Does This Mean for Cancer Treatment? Almost 2 million new cancer cases were reported in the United States in 2022. In 2023, more than 600,000 people died of cancer, according to the Centers for Disease Control and Prevention (CDC) data. Cancer is the second leading cause of death in the U.S., behind heart disease. In 2022, cancer accounted for almost 19 percent of deaths in the country, according to Statista data. Cancer vaccines have been approved in the past, such as Provenge, the Seattle biotech company Dendreon's shot used to treat certain forms of advanced prostate cancer. There are also others currently undergoing the clinical trial process, such as Moderna's experimental mRNA-4157 cancer vaccine, which aims to prevent the recurrence of melanoma and lung cancer and has progressed to Phase 3 in its clinical trials. However, what makes this new study notable is the fact that it is one step closer to researchers finding a vaccine to treat all types of cancer, rather than a specific type. "This strategy could be a promising neoadjuvant therapy prior to checkpoint blockades or other cancer therapies," Hua Wang, a professor of materials science and engineering at the University of Illinois Urbana-Champaign, told Newsweek. "With more success of personalized cancer vaccines, the researchers, clinicians, and the patient community will hopefully gain more confidence in cancer vaccines," Wang, who is not associated with the study, said. "At that stage, the goal of developing a universal cancer vaccine will be more reachable." Braun deemed the study "exciting early data," but told Newsweek it still has "a long path to having a major impact on the treatment of cancers in individuals." Potential Challenges While the findings are a "promising" breakthrough in cancer research, Wang said that still "rigorous safety evaluations and the optimization for therapeutic benefits are needed before this strategy can move forward." "Generally speaking, every one of us is hoping for a universal cancer vaccine that can treat or prevent different types of cancers," he said. However, Wang added that practically, "personalized" cancer vaccines are "more likely to cross the finish line because of the higher specificity and thus less off-target effects." While many types of cancer vaccines are currently being tested in clinical trials, Wang said that the challenge largely lies in "the balance of therapeutic benefits and safety." Another key issue is that "very few researchers have the resources and support needed to push forward a clinical trial on cancer vaccine," he added. Braun also said that, while cancer vaccines hold "tremendous promise," they also raise a number of open questions. "What are the best targets for the vaccine, or are more universal vaccines possible?" he said. "In what setting would a vaccine be most effective? What other types of treatments should be given together with the vaccine?" He added that in the coming years, "it will be critical to answers these questions while also having definitive clinical studies to prove that cancer vaccines help patients to live longer." Full Interview Below Q1: What does this study mean for the general public? How could this change the prevalence and treatment of cancer? Hua Wang, a professor of materials science and engineering at the University of Illinois Urbana-Champaign: "This paper reports that the early stimulation of IFN-I pathways could increase the sensitivity of poorly-immunogenic tumors to checkpoint blockades. The researchers performed the IFN-I stimulation by using unmodified mRNAs (without a specific target). This strategy could be a promising neoadjuvant therapy prior to checkpoint blockades or other cancer therapies. However, rigorous safety evaluations and the optimization for therapeutic benefits are still needed before this strategy can move forward." David Braun, a professor of medicine and member of the Center of Molecular and Cellular Oncology at Yale Cancer Center: "This study has two important goals: (1) to understand why current immune-based treatments work so well in some patients, and (2) to try to use that knowledge to design new immune treatments. In animal models, the research team is able to make tumors more sensitivity to immune therapy using this new approach. While exciting early data, we do have to remember that this is early work in animal studies, and so there is still a long path to having a major impact on the treatment of cancers in individuals." Q2: How long do you think it will be before a universal cancer vaccine is made? Wang: "Generally speaking, every one of us is hoping for a universal cancer vaccine that can treat or prevent different types of cancers. However, practically, personalized cancer vaccines are more likely to cross the finish line because of the higher specificity and thus less off-target effects. With more success of personalized cancer vaccines, the researchers, clinicians, and the patient community will hopefully gain more confidence in cancer vaccines. At that stage, the goal of developing a universal cancer vaccine will be more reachable." Braun: "When most people think of vaccines, they think of 'preventive' vaccines—the kind that children and adults typically receive to prevent or lessen the impact of certain infectious diseases. While there are some of those efforts in cancer as well, the majority of efforts are focused on 'therapeutic' vaccines, which are used to try to treat cancer once it develops. Most cancer vaccines try to 'steer' the immune system to attack a patient's cancer, which makes it very difficult to create a universal vaccine. In this study, the research team proposes a major general form of vaccination—the idea that the vaccination itself, somewhat irrespective of what it is targeting, might stimulate the immune system enough to attack cancer. It is a very intriguing idea, but would need to be tested very carefully in clinical studies." Q3: Can you foresee any challenges in the development of a cancer vaccine? If so, what are they? Wang: "Various types of cancer vaccines including neoantigen mRNA vaccines, dendritic cell vaccines, tumor exosome vaccines, nanomaterial vaccines, and biomaterial scaffold vaccines are being tested in clinical trials at the moment. The challenge largely lies in the balance of therapeutic benefits and safety, and varies for each vaccine platform. One dramatic challenge, in my opinion, is the overwhelming bar to pursuing the clinical translation of promising cancer vaccines. Very few researchers have the resources and support needed to push forward a clinical trial on cancer vaccine." Braun: "Cancer vaccines hold tremendous promise to 'steer' the immune system to attack cancer cells, but there are a number of open questions. What are the best targets for the vaccine, or are more 'universal' vaccines possible? In what setting would a vaccine be most effective? What other types of treatments should be given together with the vaccine? In the coming years, it will be critical to answer these questions while also having definitive clinical studies to prove that cancer vaccines help patients to live longer."
Economic Times
19-07-2025
- Health
- Economic Times
Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumours
A new approach to cancer treatment Towards a universal cancer vaccine Live Events Building on past research (You can now subscribe to our (You can now subscribe to our Economic Times WhatsApp channel In a major development in cancer research , scientists at the University of Florida have created an experimental mRNA vaccine that stimulates the immune system to attack tumours. According to a study published in Nature Biomedical Engineering, the vaccine, when used alongside immune checkpoint inhibitors, produced a strong antitumor effect in vaccine does not target specific cancer proteins. Instead, it activates the immune system in the same way it would respond to a virus. Researchers found that the vaccine increased the levels of a protein called PD-L1 within tumours, making them more sensitive to Elias Sayour, a paediatric oncologist at UF Health and the lead researcher, said this development could lead to a new form of cancer treatment that does not rely entirely on surgery, radiation, or chemotherapy. The research was supported by the National Institutes of Health and other leading institutions.'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects,' said Sayour, who is also the principal investigator at the RNA Engineering Laboratory at UF's Preston A. Wells Jr. Center for Brain Tumor added, 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccine s to sensitise the immune system against a patient's individual tumor.'The research challenges the two current approaches in cancer-vaccine development: targeting common proteins found in cancer patients or customising a vaccine for each patient. This study suggests a third path that focuses on stimulating a broad immune response.'This study suggests a third emerging paradigm,' said Duane Mitchell, MD, PhD, a co-author of the paper. 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine .'Sayour has spent more than eight years developing mRNA-based cancer vaccines using lipid nanoparticles. These vaccines work by delivering messenger RNA (mRNA), a molecule that instructs cells to make specific proteins, into the body to prompt an immune year, Sayour's lab conducted a human trial using a personalised mRNA vaccine made from a patient's own tumour cells. The treatment quickly activated the immune system to fight glioblastoma, a deadly brain cancer. The new study builds on that work by testing a generalised mRNA vaccine, not specific to any virus or cancer formulation of this new vaccine is similar to the technology used in COVID-19 vaccines but is designed to prompt a general immune response rather than target a specific protein like the COVID spike the vaccine shows similar results in future human studies, it could lead to a universal tool in the fight against cancer.
Time of India
19-07-2025
- Health
- Time of India
Cancer cure found? Scientists create a new mRNA vaccine that triggers strong anticancer immune response against tumours
In a major development in cancer research , scientists at the University of Florida have created an experimental mRNA vaccine that stimulates the immune system to attack tumours. According to a study published in Nature Biomedical Engineering, the vaccine, when used alongside immune checkpoint inhibitors, produced a strong antitumor effect in mice. The vaccine does not target specific cancer proteins. Instead, it activates the immune system in the same way it would respond to a virus. Researchers found that the vaccine increased the levels of a protein called PD-L1 within tumours, making them more sensitive to immunotherapy. Explore courses from Top Institutes in Select a Course Category Public Policy CXO PGDM Others Leadership MCA Data Science Management Product Management Degree Design Thinking Data Science Cybersecurity others Finance Digital Marketing Technology Artificial Intelligence Healthcare MBA Data Analytics Project Management Operations Management healthcare Skills you'll gain: Duration: 12 Months IIM Calcutta Executive Programme in Public Policy and Management Starts on undefined Get Details Skills you'll gain: Economics for Public Policy Making Quantitative Techniques Public & Project Finance Law, Health & Urban Development Policy Duration: 12 Months IIM Kozhikode Professional Certificate Programme in Public Policy Management Starts on Mar 3, 2024 Get Details A new approach to cancer treatment Dr. Elias Sayour, a paediatric oncologist at UF Health and the lead researcher, said this development could lead to a new form of cancer treatment that does not rely entirely on surgery, radiation, or chemotherapy. The research was supported by the National Institutes of Health and other leading institutions. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Undo 'This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus – so long as it is an mRNA vaccine – could lead to tumor-specific effects,' said Sayour, who is also the principal investigator at the RNA Engineering Laboratory at UF's Preston A. Wells Jr. Center for Brain Tumor Therapy. Towards a universal cancer vaccine Sayour added, 'This finding is a proof of concept that these vaccines potentially could be commercialised as universal cancer vaccine s to sensitise the immune system against a patient's individual tumor.' Live Events The research challenges the two current approaches in cancer-vaccine development: targeting common proteins found in cancer patients or customising a vaccine for each patient. This study suggests a third path that focuses on stimulating a broad immune response. 'This study suggests a third emerging paradigm,' said Duane Mitchell, MD, PhD, a co-author of the paper. 'What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine .' Building on past research Sayour has spent more than eight years developing mRNA-based cancer vaccines using lipid nanoparticles. These vaccines work by delivering messenger RNA (mRNA), a molecule that instructs cells to make specific proteins, into the body to prompt an immune reaction. Last year, Sayour's lab conducted a human trial using a personalised mRNA vaccine made from a patient's own tumour cells. The treatment quickly activated the immune system to fight glioblastoma, a deadly brain cancer. The new study builds on that work by testing a generalised mRNA vaccine, not specific to any virus or cancer mutation. The formulation of this new vaccine is similar to the technology used in COVID-19 vaccines but is designed to prompt a general immune response rather than target a specific protein like the COVID spike protein. If the vaccine shows similar results in future human studies, it could lead to a universal tool in the fight against cancer.
NDTV
18-07-2025
- Health
- NDTV
Could This Be The End Of Cancer? Scientists Develop Revolutionary mRNA Vaccine
In a significant advancement in cancer research, scientists at the University of Florida have developed an experimental mRNA vaccine that enhances the body's immune response against tumours. The study, published in Nature Biomedical Engineering, shows that this vaccine, when combined with standard immunotherapy drugs known as immune checkpoint inhibitors, produced a strong antitumor effect in mice. What makes the finding especially promising is that the vaccine doesn't target specific tumour proteins. Instead, it activates the immune system as if it were fighting a virus. This effect was achieved by boosting the expression of a protein called PD-L1 within tumours, which made them more responsive to treatment. Lead researcher Dr. Elias Sayour, a paediatric oncologist at UF Health, said in a news release this discovery could lead to a new way of treating cancer without relying solely on surgery, radiation, or chemotherapy. The study was supported by the National Institutes of Health and other major institutions. If future studies in humans show similar results, the research could pave the way for a universal cancer vaccine that helps treat many types of difficult, treatment-resistant cancers. "This paper describes a very unexpected and exciting observation: that even a vaccine not specific to any particular tumor or virus - so long as it is an mRNA vaccine - could lead to tumor-specific effects," said Sayour, principal investigator at the RNA Engineering Laboratory within UF's Preston A. Wells Jr. Center for Brain Tumor Therapy. "This finding is a proof of concept that these vaccines potentially could be commercialized as universal cancer vaccines to sensitize the immune system against a patient's individual tumor," said Sayour, a McKnight Brain Institute investigator and co-leader of a program in immuno-oncology and microbiome research. Until now, there have been two main ideas in cancer-vaccine development: to find a specific target expressed in many people with cancer or to tailor a vaccine that is specific to targets expressed within a patient's own cancer. "This study suggests a third emerging paradigm," said Duane Mitchell, MD, PhD, a co-author of the paper. "What we found is by using a vaccine designed not to target cancer specifically but rather to stimulate a strong immunologic response, we could elicit a very strong anticancer reaction. And so this has significant potential to be broadly used across cancer patients, even possibly leading us to an off-the-shelf cancer vaccine." For more than eight years, Sayour has pioneered high-tech anticancer vaccines by combining lipid nanoparticles and mRNA. Short for messenger RNA, mRNA is found inside every cell, including tumour cells, and serves as a blueprint for protein production. This new study builds upon a breakthrough last year by Sayour's lab: In a first-ever human clinical trial, an mRNA vaccine quickly reprogrammed the immune system to attack glioblastoma, an aggressive brain tumour with a dismal prognosis. Among the most impressive findings in the four-patient trial was how quickly the new method, which used a "specific" or personalised vaccine made using a patient's own tumour cells, spurred a vigorous immune system response to reject the tumour. In the latest study, Sayour's research team adapted their technology to test a "generalised" mRNA vaccine, meaning it was not aimed at a specific virus or mutated cells of cancer but engineered simply to prompt a strong immune system response. The mRNA formulation was made similarly to the COVID-19 vaccines, rooted in similar technology, but wasn't aimed directly at the well-known spike protein of COVID.
